DCF Advisers’s Bristol-Myers Squibb BMY Stock Holding History

DCF Advisers’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4,000	Closed	-$232K	–	90
2023 Q3	$232K	Buy	+4,000	New	+$245K	0.13%	82

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

DCF Advisers's BMY Position: Q4 2023 in Review

DCF Advisers sold out of Bristol-Myers Squibb (BMY) in Q4 2023, closing a stake of 5,250 shares — an estimated $305K sold.

DCF Advisers first reported a position in BMY in Q4 2019 and held it in 10 quarters. The position peaked at $3.82M in Q4 2019. 2,364 funds tracked by Wall St. Rank hold BMY as of Q4 2023.

DCF Advisers reported no remaining Bristol-Myers Squibb position as of Q4 2023 after selling out during the quarter.
DCF Advisers sold 5,250 Bristol-Myers Squibb shares in Q4 2023, an estimated $305K.
DCF Advisers first reported a position in Bristol-Myers Squibb in Q4 2019 and held it in 10 quarters.
DCF Advisers's Bristol-Myers Squibb position peaked at $3.82M in Q4 2019.
2,364 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2023.

Based on DCF Advisers's 13F filing for Q4 2023, filed 13 Feb 2024.